ClinicalTrials.gg
CompletedNCT02725086Updated Nov 10, 2016

Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers

A Phase 1 interventional study of Leucostim® and Neupogen® in Healthy, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-10.

Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

A Randomized, Open-label, Two-way Crossover, Open-label Clinical Trial to Compare Pharmacokinetic/Pharmacodynamic Properties and Safety after Subcutaneous Administration of Leucostim® and Neupogen® in Healthy Adult Volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 - 45 years
  • 18.5 - 25.0 kg/m2
  • Value of (absolute neutrophil count) had to be inside the normality range at the screening

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history or presence of reaction to drugs (G-CSF) or their ingredients/additives
  • Subjects with a clinically relevant history of allergic reaction
  • Subjects with a history of acute infectious diseases within 2 weeks prior to administration of investigational products
  • At the investigator's discretion, subjects who is considered inappropriate to participate in the study due to any conditions including screening results
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Part 1; Filgrastim 5 ㎍/kg

    Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.

    Drug: Leucostim® · Drug: Neupogen®

  • Experimental
    Part 2; Filgrastim 10 ㎍/kg

    Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.

    Drug: Leucostim® · Drug: Neupogen®

Interventions

06

What researchers measure

Primary outcomes

  1. AUCinf of Filgrastim

    PK parameter

    Time frame: 0~48 hr

  2. Cmax of Filgrastim

    PK parameter

    Time frame: 0~48 hr

  3. AUEC0-t of ANC(absolute neutrophil count)

    PD parameter

    Time frame: 0~120 hr

  4. Emax of ANC(absolute neutrophil count)

    PD parameter

    Time frame: 0~120 hr

Secondary outcomes

  1. Tmax of Filgrastim

    PK parameter

    Time frame: 0~48 hr

  2. AUC0-t of Filgrastim

    PK parameter

    Time frame: 0~48 hr

  3. CL/F of Filgrastim

    PK parameter

    Time frame: 0~48 hr

  4. Vd/F of Filgrastim

    PD parameter

    Time frame: 0~48 hr

  5. AUEC0-t of CD34+ cell count

    PD parameter

    Time frame: 0~312 hr

  6. Emax of CD34+ cell count

    PD parameter

    Time frame: 0~312 hr

07

Study locations

1 site
  • Severance Hospital, Yonsei University College of Medicine
    Seoul, Seodamun-gu 03722, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Apr 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2016
First posted
Mar 31, 2016
Start
Feb 2016
Primary completionActual
Apr 2016
CompletionActual
May 2016
Last update
Nov 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02725086
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Feb 2016
Primary completion
Apr 2016
Completion
May 2016
Last update
Nov 10, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion